Abingdon Health is excited to declare its growth at its York headquarters in the UK follows more investment in state-of-the-art lateral flow automation.
FREMONT, CA: Abingdon Health is delighted to declare that further growth at its York headquarters in the UK follows more investment in state-of-the-art lateral flow automation. This will offer a significant rise in its manufacturing footprint, which will result in Europe’s largest facility for rapid test manufacturing. This news has come weeks after the UK Government revealed Abingdon Health as one of the leading members of the UK Rapid Test Consortium (UK-RTC).
Prior to this year, Abingdon Health has announced an initial round of growth in York after 90 % revenue growth in 2019. The credit goes to their new assay developments, and assay manufacturing contract wins, and the presentation of its AppDx Smartphone reader software. In April 2020, the expansion continued with the procurement of a new lateral flow manufacturing facility in Doncaster, UK. This latest development and investment in equipment has been secured in a new video, that will come as 2020 sees continuous high demand for Abingdon Health’s services.
Abingdon Health’s two manufacturing spots in York and Doncaster can generate millions of rapid tests per month for clients across many industries. This adaptable, dual-site method forms a peace-of-mind solution to make sure that the customers obtain product stability and a secured supply during routine scheduling and spikes in demand.
Michael Hunter, Operations Director of Abingdon Health, commented, “The additional footprint and automation come at a timely moment as demand for rapid tests is growing rapidly, with the market likely to exceed $10bn globally. Our precision automation and multi-site approach means we can adapt to meet the varying manufacturing needs of our growing global client base.”